Effect of Hydralazine on duration of soft tissue local anesthesia following dental treatment

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201312202877N2

Enrollment

Registered

2014-02-08

Start date

2013-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effectiveness of Hydralazine HCl on the adverse effect of local anesthesia. Local anaesthetics

Interventions

Intervention 1: Control group: completion of the dental treatment, patients randomly received a Sham injection in the same site as the local anesthetic injection. Intervention 2: Intervention group:

Treatment - Drugs

Control group: completion of the dental treatment, patients randomly received a Sham injection in the same site as the local anesthetic injection

Intervention group: completion of the dental treatment, patients randomly received a Hydralazine HCl injection in the same site as the local anesthetic injection 4 mg/ml Hyd

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Male or female greater than or equal to 18 years; Sufficiently healthy, as determined by the Investigator, to receive routine dental care; Requires one or two cartridges of local anesthesia administered by inferior alveolar nerve block techniques; Understands and gives written informed consent; Can communicate with the Investigator and study staff, and can understand and comply with the requirements of the protocol Exclusion Criteria: History or presence of any condition that contraindicates routine dental care; Concurrent conditions: any incapacitating medical condition (e.g. unstable angina, uncontrolled cardiac arrhythmias, uncontrolled hypertension, uncontrolled hyperthyroidism); significant infection or inflammatory process of the oral cavity; Concomitant medications: use of an opioid or opioid-like analgesic (e.g. codeine, tramadol, pentazocine) within 48 hours prior to administration of anesthetic; Allergy or intolerance to lidocaine, articaine, prilocaine, mepivacaine, epinephrine, levonordefrin, sulfites, phentolamine, or topical benzocaine; Any condition which, in the opinion of the Investigator, increases the risk to the subject of participating in this study or decreases the likelihood of compliance with the protocol

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Soft tissue local anesthesia. Timepoint: Just one day. Method of measurement: ?Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactOmid Fakheran

Isfahan University of Medical Sciences

fakheran@dnt.mui.ac.ir+98 31 1661 9472

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026